Ovarian cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

24 of 39+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, United States· US$43,146 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$674,142 awarded in fiscal year 2026· until Aug 2031

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, United States· US$377,257 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Germany· EU contribution €202,125· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, France· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Italy· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Austria· EU contribution €3,977,586· until Sept 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, United Kingdom· EU contribution €7,998,791· until May 2029· 3 countries

10 of 659 running projects, newest first. Listed amounts together: US$367.4m + €54.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

  NCT04149145· University of Alabama at Birmingham· Updated 5 Jun 2026

  “never opened”Registry text, quoted unchanged. Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

• Withdrawn

  Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

  NCT06120972· Alexander B Olawaiye, MD· Updated 12 Feb 2025

  “Sponsor terminated due to Olaparib losing patent”Registry text, quoted unchanged. Source

• Terminated

  Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

  NCT03891576· Mario Negri Institute for Pharmacological Research· Updated 17 Jan 2025

  “Low accrual rate”Registry text, quoted unchanged. Source

• Terminated

  Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

  NCT04826198· Gustave Roussy, Cancer Campus, Grand Paris· Updated 5 Dec 2024

  “Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an improved version, and the contract ensuring access to this molecule has expired.”Registry text, quoted unchanged. Source

• Withdrawn

  ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

  NCT06161493· Haider Mahdi· Updated 15 Oct 2024

  “Investigator Discretion”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

  NCT06065059· Tango Therapeutics, Inc.· Updated 13 Aug 2024

  “Terminated due to safety”Registry text, quoted unchanged. Source

• Terminated

  ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

  NCT04267939· Bayer· Updated 21 Dec 2023

  “There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

  NCT07743164· Merck Sharp & Dohme LLC· Source

• Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· AstraZeneca· Source

• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· EMD Serono Research & Development Institute, Inc.· Source

• Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

  NCT04034927· National Cancer Institute (NCI)· Source

• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

  NCT01081951· AstraZeneca· Source

• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· AstraZeneca· Source

• REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

  NCT06710548· Dana-Farber Cancer Institute· Source

• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

  NCT01844986· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis.

  Nat Commun, Sept 2026

• CRISPR/Cas in gynecologic cancers: A review of experimental and therapeutic applications.

  Indian J Cancer, Jun 2026

• USP18 Impacts Cisplatin Resistance in Ovarian Cancer Cells by Modulating DNA Repair.

  Int J Biol Sci, May 2026

• Knockout of filamin A in KGN granulosa tumor cells impairs proliferation, cell cycle progression, migration, and cytoskeletal organization under mechanical stress.

  Biol Res, May 2026

• Transcriptomic analysis of zonula occludens-1 (ZO-1) knockout in ovarian cancer cell lines.

  Genes Genomics, Mar 2026

• Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching.

  Protein Cell, Mar 2026

• Magnetic Fe3O4-Au@UIO-66-NH2@toehold probe mediated fluorescent sensor for detecting ovarian cancer-specific circRNA coupled with hybridization chain reaction and the CRISPR-Cas12a system.

  Biosens Bioelectron, Feb 2026

• Ovarian Cancer Susceptibility and Chemosensitivity to KRAS Modulation.

  Int J Mol Sci, Feb 2026

• In-Tumor CRISPR-Cas9 Knockout Screening and Novel Therapy Development for Malignant Transformation of Ovarian Teratoma.

  Cancer Sci, Jan 2026

• Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters.

  Theranostics, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.